NBRV down 16.6% Today - Market Remains Tough on Companies Developing New Antibiotics


The market has been very tough on small cap companies developing novel anti-microbials (e.g. antibiotics) since this past fall (See CDTX and PRTK for example). Therefore, ahead of NBRV's phase 3 data readout for the oral version of its novel antibiotic today, we dug deeper into earlier phase data for this oral formulation and saw some gastro-intestinal adverse events that made us worried about the market reaction, as we reported in our catalyst calendar on March 29. The data and market confirmed our fear today, as the market seemed to ignore generally positive efficacy data and focus on mostly mild adverse event data to drive the stock down 16.6% today. Fortunately, we closed our NBRV position in our Amp hypothetical portfolio ahead of today's data readout.

#AmpFree

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon